🇺🇸 FDA
Pipeline program

Topical Beremagene Geperpavec

B-VEC-03

Phase 3 mab completed

Quick answer

Topical Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa is a Phase 3 program (mab) at Krystal Biotech with 2 ClinicalTrials.gov record(s).

Program details

Company
Krystal Biotech
Indication
Dystrophic Epidermolysis Bullosa
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials